Monopar Therapeutics
MNPR
74 hedge funds and large institutions have $361M invested in Monopar Therapeutics in 2025 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 33 increasing their positions, 9 reducing their positions, and 5 closing their positions.
360% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 5
267% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 9
32% more funds holding
Funds holding: 56 → 74 (+18)
12.43% more ownership
Funds ownership: 70.28% → 82.71% (+12%)
2% more capital invested
Capital invested by funds: $354M → $361M (+$6.5M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$17.3M |
| 2 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$13.9M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$12.7M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$8.64M |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$8.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
-$6.49M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$5.26M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.53M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.61M |
| 5 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$906K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$353K | -4,328 | Closed |
|
77
State Board of Administration of Florida Retirement System
Tallahassee,
Florida
| – | -$286K | -3,508 | Closed |
|
|
AAP
78
Arax Advisory Partners
Denver,
Colorado
| – | -$1.14K | -14 | Closed |
|
MNPR Hedge Fund Activity: Q4 2025 in Review
74 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q4 2025, worth a combined $361M — up 1.8% from $354M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new MNPR positions and 5 closed out — a net gain of 18 holders — while 33 added to existing stakes and 9 trimmed.
The largest buyer was Siren LLC, opening a new position worth an estimated $17.3M. The largest seller was Affinity Asset Advisors, exiting entirely with an estimated $6.49M sold.
- 74 institutional investors held Monopar Therapeutics (MNPR) as of Q4 2025, up from 56 in Q3 2025.
- Funds reported $361M of Monopar Therapeutics stock for Q4 2025, up 1.8% quarter-over-quarter.
- 23 funds opened new Monopar Therapeutics positions in Q4 2025 and 5 closed out, a net change of +18 holders.
- The largest Monopar Therapeutics buyer in Q4 2025 was Siren LLC, an estimated $17.3M added.
- The largest Monopar Therapeutics seller in Q4 2025 was Affinity Asset Advisors, an estimated $6.49M sold.
Based on aggregated 13F filings for Q4 2025.